Zacks.com on MSN

Why Merck's 32% Rally Isn't Enough to Change the Bearish View

MRK is up over 32% in three months, but declining estimates, Keytruda's upcoming LOE and Gardasil declines keep the stock ...

Disrupting Biotech: Jurek Kozyra Unveils DNA Nanorobots That Could Cure the Incurable

Bringing a new drug from discovery to market is a grueling marathon that typically requires 10–15 years of research, testing, and regulatory approval. According to recent data, clinical development ...